Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 3;4(3):207-211.
doi: 10.1515/almed-2023-0082. eCollection 2023 Sep.

A new approach to prostate cancer screening

Xavier Filella  1 , Álvaro González  2 , Josep Maria Augé  1 , Antonio Barco  3 , Rosa Carbonell  4 , María Jesús Gaspar  5 , Antonio Martínez-Peinado  6 , Clara Pérez Barrios  7 , Marta Sánchez-Carbayo  8 , José Diego Santotoribio  9 , Jaume Trapé  10 ; Comisión de Marcadores Biológicos de Cáncer, SEQCML
Affiliations

A new approach to prostate cancer screening

Xavier Filella et al. Adv Lab Med. .

Abstract

Prostate cancer screening based on prostate-specific antigen (PSA) testing has been a matter of controversy. Although screening for prostate cancer was effective in reducing mortality, it resulted in overdiagnosis, which translated into unnecessary treatments and numerous adverse effects. As a result, recommendations from scientific societies became increasingly restrictive. In the recent years, new approaches to prostate cancer screening have been proposed. These new approaches are aimed at solving the controversy between widespread screening vs. no screening, and reconsidering PSA testing as a screening tool with a good benefit/risk balance. In this context, the European Association of Urology submitted a proposal to the European Commission for prostate cancer screening to be performed as a function of baseline PSA concentrations. The European Commission recently recommended the implementation of organized prostate cancer screening programs for men aged ≤70 years based on PSA values in combination with follow-up magnetic resonance imaging.

Keywords: PSA; prostate cancer; screening.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors state no conflict of interest.

References

    1. Sociedad Española de Oncología Médica. . Las cifras del cáncer en España 2022. SEOM.https://seom.org/publicaciones/el-cancer-en-espanyacom [Acceso 20 abril 2023]
    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–35. doi: 10.1016/s0140-6736(14)60525-0. - DOI - PMC - PubMed
    1. Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43–51. doi: 10.1016/j.eururo.2019.02.009. - DOI - PMC - PubMed
    1. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32. doi: 10.1093/jnci/djr500. - DOI - PMC - PubMed
    1. Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019;123:854–60. doi: 10.1111/bju.14580. - DOI - PMC - PubMed

LinkOut - more resources